You are here

Our science / Clinical Trials / Find a Trial / NCT00167999

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Back to Search Print Save as PDF Bookmark Trial

NCT00167999

Last updated on November 19, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Seoul, , 133-792 Korea, Republic of
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
15 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eligible patients of either sex, 15 years of age or older

- Patients who are admitted to the department of hematology and oncology

- Provide written informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have hypersensitivity to ?-lactam antibiotics

- Female who are pregnant or breast-feeding

- Any underlying conditions or non-infectious diseases that will be ultimately fatal
within 30 days

NCT00167999
Pfizer
Completed
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search
Descriptive Information
Brief TitleStudy Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Official TitleEffects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
Brief SummaryTo determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNot Provided
Study PopulationNot Provided
Condition
  • Gram-Positive Bacterial Infections
  • Escherichia Coli Infections
  • Klebsiella Infections
InterventionDrug: piperacillin-tazobactam
Study Groups/CohortsNot Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Enrollment
 (submitted: September 11, 2005)		200
Original EnrollmentSame as current
Study Completion DateNot Provided
Primary Completion DateNot Provided
Eligibility Criteria

Inclusion Criteria:

  • Eligible patients of either sex, 15 years of age or older
  • Patients who are admitted to the department of hematology and oncology
  • Provide written informed consent

Exclusion Criteria:

  • Patients who have hypersensitivity to ?-lactam antibiotics
  • Female who are pregnant or breast-feeding
  • Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
Sex/Gender
Sexes Eligible for Study:All
Ages15 Years and older   (Child, Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesKorea, Republic of
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00167999
Other Study ID Numbers0910X-101676
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyNot Provided
Study SponsorWyeth is now a wholly owned subsidiary of Pfizer
CollaboratorsNot Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateMarch 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now